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Abstract  
Thymol is a monoterpene that specifically interacts with synaptic neural functions in 
neuronal GABA-operated Cl- channels. Here we explore the effects of thymol, and 
propofol as positive control, on t-[35S]butylbicyclophosphorothionate ([35S]TBPS) 
binding in primary cultures of cortical neurons. The study includes a meaningful 
analysis of the effect of various exposure buffers, and their correlation with GABA 
released from cells, chloride influx through the GABAA receptor and GABA transporter 
activity. Cell viability was also determined. Thymol and propofol inhibited the binding 
of [35S]TBPS to cells exposed to Tris-citrate-NaCl buffer whereas a biphasic effect was 
observed in HEPES solution. The different effects of the two buffers analysed are due to 
the higher capacity of Tris-citrate-NaCl buffer to induce the release of endogenous 
GABA facilitating the binding of [35S]TBPS to its recognition site at the GABAA 
receptor. Released GABA in the presence of this buffer was inhibited by the neuronal 
GABA transporter inhibitor SKF 100330-A. Tris-citrate-NaCl buffer also induced a 
chloride influx, which was reverted by picrotoxinin. TBPS binding in living cells is 
facilitated by GABA released from the cells, which in turn activates basal GABAA 
receptor activity. The results deepen on the allosteric mechanism of thymol as positive 
modulator of the GABAA receptor. Furthermore, we corroborate [35S]TBPS binding as 
an important test to verify the capacity of drugs to act on and recognize a site at the 
GABAA receptor. 
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1. Introduction 
 
Thymol (2-isopropyl-5-methylphenol) is a monoterpene that is found as a component of 
many essential oils (Gomes-Carneiro et al., 1998). It is widely used in dental practice 
and in anaesthetic halothane preparations due to its anti-microbial and antioxidant 
properties (Shapiro and Guggenheim, 1995; MacPherson, 2001; Burt, 2004). Interest in 
isolated monoterpenes has been growing in recent years because of their possible 
pharmaceutical utility. In particular, this compound specifically interacts with synaptic 
neural functions on neuronal Na+ and GABA-operated Cl- channels (Mohammadi et al., 
2001; Haeseler et al., 2002; Priestley et al., 2003; García et al., 2006) as well as with 
nociception-sensitive receptor channels (Lee et al., 2008). Its capacity to increase 
[3H]flunitrazepam binding to its specific site in the GABAA receptor by using 
synaptosomal membranes or cultured cortical neurons has been described (Sánchez et 
al., 2004; García et al., 2006). We also demonstrated the ability of thymol to both 
enhance GABA-induced chloride influx and open the chloride channel in the GABAA 
receptor in the absence of GABA. The fact that this monoterpene did not inhibit 
[3H]muscimol binding (it even showed a slight increase) and increased 
[3H]flunitrazepam binding argues strongly for its recognition site in the receptor being 
different from the one for GABA and benzodiazepines. Its structural properties, which 
resemble those of propofol suggest a close or common recognition site in the receptor 
(García et al., 2006).  
Positive allosteric modulators of the GABAA receptor increase both [3H]muscimol and 
[3H]flunitrazepam binding and modify t-[35S]butylbicyclophosphorothionate 
([35S]TBPS) binding (Vale et al., 1997; Hawkinson et al., 1998; Zeng et al., 2005; Suñol 
et al., 2006). [35S]TBPS recognizes a site in the GABAA receptor that binds the 
convulsant picrotoxin; and it is well established that positive allosteric modulators that 
activate the GABAA receptor Cl- channel also allosterically modify this site (Ghiani, 
1996; Kalueff, 2007). In this work we explore the effects of thymol, with propofol as 
positive control, on [35S]TBPS binding in primary cultures of cortical neurons in order 
to gain a deeper insight into its mechanism of action. TBPS binding is a powerful tool 
widely used to study the interaction of a drug with the GABAA receptor. The study also 
includes an analysis of the effect of various exposure buffers on this binding assay in 
living cultured cells and its correlation with GABA released from intact cells and 
chloride influx through the GABAA receptor. 
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 2. Methods 
 
2.1. Materials 
Pregnant NMRI mice (16th day of gestation) were obtained from Charles River, Iffa 
Credo (St. Germain-sur-l’Arbreste, France). Plastic multi-well culture plates were 
purchased from CoStar (Corning Science Products, Acton, MA, USA). Foetal calf 
serum was obtained from Gibco (Glasgow, UK) and Dulbecco’s modified Minimum 
Essential Medium (DMEM) from Biochrom (Berlin, Germany). [35S]TBPS (specific 
activity ranged from 3.4 – 6.7 TBq/mmol during the entire experimental period) and 
36Cl- (> 111 MBq/g) were procured from Perkin Elmer (Boston, MA, USA) and 
Amersham Life Sciences (Buckinghamshire, UK), respectively. Liquid scintillation 
cocktail Optiphase Hisafe 2 was obtained from Wallace Oy (Turku, Finland). Thymol, 
2,6-diisopropylphenol (propofol), GABA, picrotoxinin (PTX), 1-(4,5-dimethylthiazol-
2-yl)-3,5-diphenylformazam (MTT), trypsin, soybean trypsin inhibitor, DNAse, amino 
acids and poly-L-lysine were obtained from Sigma Chemical Co. (St Louis, MO, USA). 
All the other chemicals were of analytical grade. Propidium iodide and trypan blue 
(0.4%) were from Molecular Probes and Gibco, respectively (Invitrogen, Spain). N-
(4,4-diphenyl-3-butenyl)-guvacine (SKF-100330-A) was a gift from Smith Kline & 
French. Thymol and propofol were prepared as 400 mM stock solutions in DMSO, 
light-protected, and stored at 4ºC. Stock solutions were diluted before each experiment 
in buffered solution, maintaining a 0.25% (v/v) DMSO final concentration.   
 
2.2. Cell cultures    
Primary cultures of cortical neurons were prepared from the cerebral cortices of 16-day-
old mice foetuses, following the method described by Frandsen and Schousboe (1990). 
Pregnant animals were killed by cervical dislocation and foetuses extracted. Neocortices 
were dissected with forceps, mechanically minced, with cells then dissociated by mild 
trypsinization (0.02 % w/v) at 37ºC for 10 min followed by trituration in a DNAse 
solution (0.004% w/v) containing a soybean trypsin inhibitor (0.05% w/v). The cells 
were re-suspended in a modified DMEM solution (31 mM glucose and 0.2 mM 
glutamine), supplemented with insulin, penicillin and 10% foetal calf serum. The cell 
suspension (1.6x106 cells/ml) was seeded in 24x-multi-well plates, pre-coated with 
poly-L-lysine, and incubated for 6-9 days in a humidified 5% CO2 / 95% air atmosphere 
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at 36.8ºC. A mixture of 5 μM 5-fluoro-2’-deoxyuridine and 20 μM uridine was added 
after 48 h in culture to prevent glial proliferation.  
Animals were handled in compliance with protocols of the University of Barcelona, 
approved by the Generalitat de Catalunya, Spain, in accordance with EU guidelines, and 
in compliance with the Office of Laboratory Animal Welfare (OLAW) / National 
Institutes of Health (NIH) (identification number A5224-01). 
 
 2.3. [35S]TBPS binding 
The binding assay was performed according to Pomés et al. (1993) and Vale et al. 
(1997). Briefly, the cells were washed 3 times with 0.5 ml of HEPES buffered saline 
solution (HBSS: 136 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.4 mM MgCl, 1 mM 
NaH2PO4, 10 mM HEPES and 9 mM glucose, adjusted at pH 7.4), pre-warmed at 37ºC. 
The incubation system contained 1.5-3 nM [35S]TBPS and compound solution in either 
a Tris-citrate buffered saline solution (TCBSS: 50 mM Tris-citrate and 200 mM NaCl, 
adjusted at pH 7.4) or HBSS in a final volume of 0.25 ml. After 30 min at 25ºC the 
solution was removed and rinsed 3 times with 0.5 ml of cold HBSS solution. Non-
specific binding was measured in the presence of 200 μM PTX. Cells were collected in 
0.25 ml 0.2 M NaOH overnight and their radioactivity was determined by liquid 
scintillation counting (Optiphase ‘Hisafe’ 2). No differences were observed between 
protein content in the cultures exposed to TCBSS and those exposed to HBSS, 
measured by the Bradford method. Therefore, binding data were determined as 
dpm/culture. Specific [35S]TBPS binding values along this study were 3.2 ± 0.9 pmol/g 
protein and 28.1 ± 3.0 pmol/g protein when using HBSS or TCBSS buffers, 
respectively. 
 
2.4. Chloride influx  
Chloride influx was determined as 36Cl- uptake in intact cell cultures (Vale et al., 2003; 
García et al., 2006). Briefly, culture medium was replaced by a pre-warmed Earle’s 
balanced salt solution (EBSS: 116 mM NaCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 1 mM 
NaH2PO4, 15.2 mM NaHCO3 and 5.5 mM glucose, adjusted at pH 7.4) and cell cultures 
were incubated in a humidified 5% CO2 / 95% air atmosphere at 36.8ºC. After 30 min 
incubation, buffer was replaced by new EBSS solution and incubated for an additional 
15 min. Cells were then rinsed twice with EBSS solution and pre-incubated for 30 min 
at 25ºC with HBSS or TCBSS buffer, according to the experiment. After this, the cells 
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were incubated for 30 s with 225 µL buffer solution containing 36Cl- (0.4 μCi/ml). 
Picrotoxinin was added when indicated. After removing the 36Cl- solution, each well 
was immediately rinsed four times with 1.5 ml cold HBSS solution. Cells were lysed by 
water-induced hyposmotic shock, and radioactivity was determined by liquid 
scintillation counting, as described above.  
 
2.5. GABA determination 
GABA concentration in the exposure medium was determined by high-performance 
liquid chromatography (Babot et al., 2005) after 30 min incubation at 25ºC with HBSS 
or TCBSS (binding incubation conditions). GABA content was calculated by an 
external standard method with GABA dissolved in HBSS and TCBSS, since GABA 
fluorescence detection was different in the two buffer solutions.   
 
2.6. Cell viability 
MTT assay.- Following 7 days in vitro, the cells were exposed to HBSS or TCBSS for 
30 min at 25ºC, and their viability was determined. The assay was conducted essentially 
according to the method described by García et al. (2006). Following each exposure 
period, the cells were washed three times with 0.5 ml of pre-warmed HBSS solution 
(37ºC) and then incubated for 20 min at 37ºC with 0.25 ml MTT reagent solution (0.25 
mg/ml). After removal of the MTT solution, 0.25 ml/well of solubilization solution 
(SDS 5% w/v) was added and the cells were kept overnight at 37ºC in darkness. 
Absorbance was measured at a wavelength of 560 nm by a spectrophotometer plate 
reader (iEMS Reader MF; Labsystems, Helsinki, Finland).  
Propidium iodide and trypan blue assay.- Cells were exposed to HBSS, TCBSS, HBSS 
+ 0.3% Triton X-100 or TCBSS + 0.3% Triton X-100 for 30 min at 25ºC in the 
presence of propidium iodide (PI, 7.4 µg/mL). In parallel cultures, trypan blue was 
added at the end of the incubation period without adding propidium iodide. 
Microphotographs were taken in a fluorescence microscope equipped with phase 
contrast (Olympus YX70). Digital images of incorporated propidium iodide and trypan 
blue were captured using a ColorView camera.  
 
2.7. Data analysis 
Results are mean ± S.E.M., of 3 experiments performed in different culture 
preparations, except when otherwise stated. Each experiment was performed in 
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triplicate. Sigmoid curves were fitted to concentration-response data. A minimum of 6 
concentrations, all determined in triplicate, were used for each curve. Student’s t-test 
and one-way analysis of variance followed by Bonferroni’s test were used for 
comparing different experimental conditions. Fitting and statistical analyses used 
GraphPad Prism (GraphPad Software Inc, San Diego, CA, USA). 
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3. Results 
 
Specific [35S]TBPS binding in basal conditions, determined as the difference between 
total binding and binding in the presence of PTX, was significantly higher in cultures 
incubated with TCBSS than in those with HBSS buffer (664 ± 47 vs. 235 ± 47 
dpm/culture, respectively, P = 0.003, n = 3). This difference was because total binding 
was enhanced in TCBSS, whereas non-specific binding in the presence of PTX was 
similar in both buffers (Fig. 1A). GABA produced a biphasic effect on the specific 
[35S]TBPS binding in HBSS, significantly increasing TBPS binding at 10 µM and 
decreasing thereafter (Fig. 1B), whereas only a decreasing effect was observed in 
TCBSS (Fig. 1B).  
Fig. 2A shows the effect of thymol on specific [35S]TBPS binding in intact neocortical 
neurons.  An inhibitory effect was observed when [35S]TBPS binding was performed in 
TCBSS, whereas a biphasic effect was observed in HBSS buffer. The stimulatory effect 
in HBSS buffer was observed up to 100 μM thymol; but 200 μM thymol completely 
inhibited [35S]TBPS binding, as it did in TCBSS. Propofol inhibited [35S]TBPS binding 
in TCBSS, whereas the effect in HBSS was stimulatory up to 30 μM and then inhibitory 
up to 100 μM (Fig. 2B). IC50 values for the inhibitory effects of thymol and propofol in 
TCBSS were 25.0 ± 8.5 µM (n = 3) and 6.3 ± 1.2 µM (n = 2), respectively (mean ± 
S.D.).  
We found statistically significant differences in the extracellular GABA concentrations 
after incubating the cells with HBSS or TCBSS. While incubation with HBSS did not 
induce substantial GABA liberation, incubation with TCBSS significantly increased its 
free concentration (Figure 4). 
A leakage of intracellular GABA due to a harmful state of the cells can be ruled out 
because the viability assays did not show differences between cells incubated with 
HBSS or TCBSS. Cells with an intact membrane are able to exclude the vital dye trypan 
blue, while cells with damaged membrane take up the dye. Fig. 3A shows that cells 
incubated with TCBSS did not take up trypan blue, whereas damaged cells exposed to 
TCBSS plus 0.3% Triton X100 did (Fig. 3B). Similarly, propidium iodide, which is 
taken up by nonviable cells and binds to DNA, only labeled Triton X100-treated cells 
(Fig. 3D) but not those exposed to TCBSS (Fig. 3C). Cells incubated with HBSS also 
excluded trypan blue and did not incorporate propidium iodide (data not shown). 
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Furthermore, cell viability values, measured as MTT reduction, were 98 ± 1% (n = 2) in 
TCBSS-exposed cultures, when compared with HBSS-exposed cultures. 
We wondered whether the increase in extracellular GABA found in the cells incubated 
with TCBSS could come through reversion of the GABA transport. Fig. 4 shows that 
the neuronal GABA transporter inhibitor SKF-100330-A (Risso et al., 1996; Clausen et 
al., 2006) significantly reduced the release of GABA induced by TCBSS. 
We determined whether the presence of GABA released in the extra-cellular medium in 
the cells incubated with TCBSS activated the GABAA receptor and induced an influx of 
Cl-. Fig. 5 shows the uptake of 36Cl- measured in cells exposed to HBSS and TCBSS in 
the absence or presence of 200 µM PTX. Uptake of 36Cl- was significantly higher in 
TCBSS-exposed cultures than in HBSS-exposed ones. Furthermore, picrotoxinin 
significantly inhibited the influx of 36Cl- in cultures exposed to TCBSS (Fig. 5). 
Bicuculline also reduced 36Cl- uptake (data not shown). However, exposure to HBSS 
did not show any such difference in the presence or absence of PTX.  
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4. Discussion  
 
The GABAA receptor is the main site of action of various GABA agonists and positive 
allosteric modulators, such as muscimol, benzodiazepines, barbiturates and steroids, 
which act as anxiolytic, sedative-hypnotic, anticonvulsant or anaesthetic drugs 
(MacDonald and Olsen, 1994; Whiting, 2003). This receptor also has recognition sites 
for GABA antagonists (for review, see Kalueff, 2007), such as bicuculline, PTX, 
neurotoxic pesticides or TBPS, which can be displaced by the positive drugs mentioned 
above (Hawkinson et al., 1998; Zeng et al., 2005). In this study, we describe thymol’s 
inhibition of [35S]TBPS binding, which together with the increase of [3H]flunitrazepam 
binding (García et al. 2006), confirms its activity as an allosteric positive modulator of 
the GABAA receptor. 
We previously demonstrated that [35S]TBPS binding parameters and its inhibition by 
convulsant agents are equivalent in intact cultured cells and in cell membrane 
preparations when binding is performed in TCBSS (Pomés et al., 1993). In addition, the 
EC50 value for propofol against [35S]TBPS binding in TCBSS found in this study agrees 
with the value reported in EDTA-water dialyzed brain membranes (Squires and 
Saederup, 2000). The influence of buffer composition and washing paradigms on 
[35S]TBPS-binding parameters in brain membrane preparation, known for a long time, 
results in different affinities of TBPS for the binding sites and in different profiles of 
binding activation/inhibition for compounds that interact with the GABAA receptor 
(Squires et al., 1983; Supavilai and Karobath, 1984; Ghiani et al., 1996). In this study, 
we provide evidence that performing the [35S]TBPS binding assay in intact cultured 
cells with a physiological buffer (HBSS) decreases specific binding. Furthermore, 
thymol and propofol had a bell-shaped effect in HBSS, similar to that described for full 
and allosteric agonists in recombinant GABAA receptors (Im et al., 1994). It is 
noteworthy that exogenous added GABA increased HBSS-performed [35S]TBPS 
binding up to a value similar to that obtained using TCBSS in the absence of added 
GABA. Some authors attribute the differences in [35S]TBPS binding between different 
membrane preparations to their GABA concentrations (Squires et al., 1983; Ghiani et 
al., 1996). Ghiani et al. (1996) reported that propofol and loreclezole had a biphasic 
effect when [35S]TBPS binding was performed on washed brain membrane 
preparations, whereas only the inhibitory effect was observed on non-washed 
membranes. Others explained the biphasic effect of the GABA agonist on [35S]TBPS 
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binding according to its occupation of the high-affinity (enhancing effect) or low-
affinity (inhibitory effect) sites (Supavilai and Karobath, 1984; Im et al., 1994), with the 
latter effect associated with channel openings. Thus, TBPS would need a minimal level 
of modulation of the GABA receptor in order to bind it. It has been demonstrated that 
similar GABA concentrations to the ones determined in this study after TCBSS 
incubation induced increments in flunitrazepam binding (∼ 30% with 1 μM GABA; 
Vale et al., 1997) and in chloride uptake (∼ 20 % with 3 μM GABA; García et al., 
2006). The decrease of chloride influx by PTX and bicuculline in the presence of 
TCBSS supports the idea that the increment induced by Tris-citrate-NaCl on [35S]TBPS 
binding is caused by a GABAergic modulation.  
GABAA receptors have different levels of spontaneous activity that depend on the 
subunits expressed (McKernan and Whiting, 1996; Wooltorton et al., 1997). This 
spontaneous activity is inhibited by GABA antagonists such as PTX (for review, see 
Mortensen et al. 2003). Such behaviour could explain the fact that PTX diminished the 
36Cl- influx of cells incubated with TCBSS buffer. However, since this latter 
experimental condition induced GABA release and since there are no data about buffer 
effect on this spontaneous activity (HBSS did not show this performance), we assume 
that the PTX inhibitory effect found in this work is due to the moderate quantity of 
released GABA. It has also been reported that the protonation/desprotonation of amino 
acid residues of GABAA receptor are responsible for pH modulation of the receptor 
(Huang and Narahashi, 1996; Uusi-Oukari et al., 2004). The incubation process (30 min 
at 25ºC) did not produce changes in the pH values of the two buffers (data not shown), 
ruling out any pH effect. Thus, the higher specific TBPS binding obtained with TCBSS 
might be attributable to a higher GABA release. An important proportion of the cells in 
primary cultures of cortical neurons are GABAergic neurons (around 40%) and these 
cells express neuronal GABA transporters (Vale et al., 1999; Suñol et al., 2008). We 
propose that the GABA efflux process when using TCBSS is mediated by reversal of 
the neuronal GABA transporter, since a significant reduction of extracellular GABA 
was attained in the presence of the neuronal GABA transport inhibitor SKF-100330-A. 
As far as we know there are no reports of the interaction of Tris buffers with the GABA 
transport, but Li et al. (2002) have reported that Tris allosterically interact with the 
substrate site of the dopamine transporter, which shares with the GABA transporters the 
fact that both belong to the SLC6 gene family (Gether et al., 2006). Furthermore, lead 
inhibited the uptake of GABA and potentiated the spontaneous release of GABA from 
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motoneurons when Tris-HCl but not phosphate or carbonate buffers were used (Spence 
et al., 1985). The observed inhibition of the TCBSS-induced efflux of GABA by SKF-
100330-A, found in this work, suggest a direct effect of Tris on the neuronal GABA 
transporter. It should be noted that the tonic conductance of the GABAA receptor is 
sensitive to factors that regulate the amount of GABA surrounding the neurons, like 
neuronal and glial GABA transport (Glykys and Mody, 2007).  
Therefore, the use of TCBSS may make TBPS binding sites more accessible in the 
membrane. In the physiologic buffer HBSS, opening the GABAA receptor-operated Cl- 
channel by GABA also made TBPS binding sites accessible to the radio-labelled 
agonist. In this study we show that GABA, thymol and propofol induced first an 
increase of [35S]TBPS binding in HBSS buffer, in consonance with activation of the Cl- 
channel (García et al., 2006). Once TBPS binding sites are fully accessible, then an 
inhibitory interaction of the compound/test agent with the TBPS sites occurs, producing 
more stepped curves. 
Finally, the ability of thymol to reduce [35S]TBPS binding in TCBSS, as described in 
this paper, confirms thymol as a positive allosteric modulator of the GABAA receptor 
with a specific recognition site, which might be shared with propofol as previously 
suggested by the described pharmacophoric model (García et al., 2006). The 
pharmacophoric hypothesis includes two hydrophobic aliphatic features, one hydrogen 
bond donor group, an exclusion volume, and an aromatic ring, characteristics found in 
both molecules. The displacement potency found for thymol was 5 times lower than that 
determined for propofol, in agreement with their EC50 values for potentiating the Cl- 
influx induced by GABA (García et al., 2006). Table 1 summarizes the parameters of 
the activity of thymol and propofol on the GABAA receptor. In this study, we show that 
thymol inhibits the binding of [35S]TBPS in TCBSS buffer with an IC50 value (25 μM; 
Fig. 2A), which is close to the EC50 value obtained for the effect on GABA potentiation 
of the GABAA receptor-operated Cl- channel (12 μM; García et al., 2006). Similarly, the 
concentration of propofol that inhibited [35S]TBPS binding in TCBSS (IC50 = 6.3 μM; 
Fig. 2B) corroborates reported data on inhibition of [35S]TBPS binding in rat brain 
membranes (Ghiani et al., 1996) and on potentiation of the GABAA receptor-operated 
Cl- channel (Bali and Akabas, 2004). The direct activation of the GABAA receptor by 
thymol and propofol (EC50 values ~ 130 μM and 10-23 μM, respectively; Mohammadi 
et al., 2001; Bali and Akabas, 2004; García et al., 2006) correlates much better with the 
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potentiation of [35S]TBPS binding in HBSS buffer. Again, a similar relationship exists 
between the potentiation of [3H]flunitrazepam binding and the potentiation of 
[35S]TBPS binding in HBSS buffer by thymol and propofol (Ghiani et al., 1996; García 
et al., 2006).  
In conclusion, [35S]TBPS binding in living cells is an important test for verifying the 
capacity of drugs like thymol to act on and recognize a specific site in the GABAA 
receptor but, the interpretation of the results must take into consideration the 
methodology employed. Depending on the buffer used in the living cell assay, thymol 
had only inhibitory or both inhibitory and potentiating effects on TBPS binding. Our 
interpretation is that thymol, by increasing GABAA receptor function (García et al., 
2006) allows the full binding of [35S]TBPS binding to the receptor, and this binding site 
is later inhibited by thymol. If binding sites are fully accessible for TBPS, as it is the 
situation when TCBSS is used in the living binding assay, thymol immediately inhibits 
TBPS binding. Taken all together, the results of this and previous works (García et al., 
2006) display a clear picture of thymol acting as positive allosteric modulator of the 
GABAA receptor.  
 
 
 
Acknowledgments 
 
This study was supported by grants PI061212 and 2005-SGR-00826 (Ministry of Health 
and Generalitat de Catalunya, respectively, Spain), SECYT-UNC (Argentina) and 
CAEN-ISN. DAG is a member of CONICET (Argentina) and was recipient of a post-
doctoral fellowship from the Fundación Carolina (Spain). IV was recipient of a CSIC 
Fellowship in the I3P program, co-financed with European Social Funds.  
 
 13
References 
 
Babot, Z., Cristòfol, R.M., Suñol, C., 2005. Excitotoxic death induced by released 
glutamate in depolarized primary cultures of mouse cerebellar granule cells is 
dependent on GABAA receptors and niflumic acid-sensitive chloride channels. Eur. J. 
Neurosci. 21, 103–112. 
Bali, M., Akabas, M.H., 2004. Defining the propofol binding site location on the 
GABAA receptor. Mol. Pharmacol.  65, 68-76. 
Burt, S., 2004. Essential oils: their antibacterial properties and potential applications in 
foods - a review. Int. J. Food. Microbiol. 94, 223-253. 
Clausen, R.P., Frølund, B., Larsson, O.M., Schousboe, A., Krogsgaard-Larsen, P., 
White, H.S., 2006. A novel selective γ-aminobutyric acid transport inhibitor 
demonstrates a functional role for GABA transporter subtype GAT2/BGT-1 in the 
CNS. Neurochem. Int. 48, 637-642. 
Davies, M., Thuynsma, R.P., Dunn, S.M.J. 1998. Effects of propofol and pentobarbital 
on ligand binding to GABAA receptor suggest a similar mechanism of action. Can. J. 
Physiol. Pharmacol. 76, 46-52. 
Frandsen, A., Schousboe, A., 1990. Development of excitatory amino acid induced 
cytotoxicity in cultured neurons. Int. J. Dev. Neurosci. 8, 209-216.  
García, D.A., Bujons, J., Vale, C., Suñol, C. 2006. Allosteric positive interaction of 
thymol with the GABAA receptor in primary cultures of mouse cortical neurons. 
Neuropharmacology 50, 25-35. 
Gether, U., Andersen, P.H., Larsson, O.M., Schousboe, A., 2006. Neurotransmitter 
transporters: molecular function of important drug targets. Trends Pharmacol. Sci. 27, 
375-383. 
Ghiani, C.A., Tuligi, G., Maciocco, E., Serra, M., Sanna, E., Biggio, G., 1996. 
Biochemical evaluations of the effects of loreclezole and propofol on the GABAA 
receptor in rat brain. Biochem. Pharmacol. 51, 1527-1534. 
Glykys, J., Mody, I., 2007. Activation of GABAA receptors: views from outside the 
synaptic cleft. Neuron 56, 763–770.  
Gomes-Carneiro, M.R., Felzenszwalb, I., Paumgartten, F.J., 1998. Mutagenicity testing 
(+/-)-camphor, 1,8-cineole, citral, citronellal, (-)-menthol and terpineol with the 
Salmonella/microsome assay.  Mutat. Res. 416, 129-136. 
Haeseler, G., Maue, D., Grosskreutz, J., Bufler, J., Nentwig, B., Piepenbrock, S., 
 14
Dengler, R., Leuwer, M., 2002. Voltage-dependent block of neuronal and skeletal 
muscle sodium channels by thymol and menthol. Eur. J. Anaesthes. 19, 571-579. 
Hawkinson, J.E., Acosta-Burruel, M., Yang, K.C., Hogenkamp, D.J., Chen, J.S., Lan, 
N.C., Drewe, J.A., Whittemore, E.R., Woodward, R.M., Carter, R.B., Upasani, R.B., 
1998. Substituted 3β-phenylethynyl derivatives of 3α-hydroxy-5α-pregnan-20-one: 
remarkably potent neuroactive steroid modulators of γ-aminobutyric acid A receptors. 
J. Pharmacol. Exp. Ther. 287, 198-207. 
Huang, C.S., Narahashi, T., 1996. Mercury chloride modulation of the GABAA 
receptor–channel complex in rat dorsal root ganglion neurons. Toxicol. Appl. 
Pharmacol. 140, 508–520.  
Im, W.B., Pregenzer, J.F., Thomsen, D.R., 1994. Effects of GABA and various 
allosteric ligands on TBPS binding to cloned rat GABAA receptor subtypes. 
Br. J. Pharmacol. 112, 1025-1030. 
Kalueff, A.V., 2007. Mapping convulsants’ binding to the GABA-A receptor chloride 
ionophore: A proposed model for channel binding sites. Neurochem. Int. 50, 61-68. 
Krasowsky, M.D., Hong, X., Hopfinger, A.J., Harrison, N.L., 2002. 4D-QSAR analysis 
of a set of propofol analogues: mapping binding sites for an anesthetic phenol on the 
GABAA receptor. J. Med. Chem. 45, 3210-3221.  
Lee, S.P., Buber, M.T., Yang, Q., Cerne, R., Cortés, R.Y., Sprous, D.G., Bryant, R.W., 
2008. Thymol and related alkyl phenols activate the hTRPA1 channel. Brit. J. 
Pharmacol. 153, 1739–1749. 
Li, L.B., Cui, X.N., Reith, M.A., 2002. Is Na+ required for the binding of dopamine, 
amphetamine, tyramine, and octopamine to the human dopamine transporter? Naunyn 
Schmiedebergs Arch. Pharmacol. 365, 303–311. 
MacDonald, R.L., Olsen, R.W., 1994. GABAA receptor channels. Annu. Rev. Neurosci. 
17, 569-602. 
MacPherson, R.D., 2001. Pharmaceutics for the anaesthetist. Anaesthesia 56, 965-979. 
McKernan, R.M., Whiting, P.J., 1996. Which GABA,-receptor subtypes really occur in 
the brain? Trends Neurosci. 19, 139-143. 
Mohammadi, B., Haeseler, G., Leuwer, M., Dengler, R., Krampfl, K., Bufler, J., 2001. 
Structural requirements of phenol derivatives for direct activation of chloride currents 
via GABAA receptors. Eur. J. Pharmacol. 421, 85-91. 
Mortensen, M., Wafford, K.A., Wingroveb, P., Ebert, B. 2003. Pharmacology of 
GABAA receptors exhibiting different levels of spontaneous activity. Eur. J. Pharm. 
 15
476, 17– 24. 
Pomés, A., Rodriguez-Farré, E., Suñol, C., 1993. Inhibition of t-
[35S]butylbicyclophosphorothionate binding by convulsant agents in primary cultures 
of cerebellar neurons. Dev. Brain Res. 73, 85-90. 
Priestley, C.M., Williamson, E.M., Wafford, K.A., Sattelle, D.B., 2003. Thymol, a 
constituent of thyme essential oil, is a positive allosteric modulator of human GABAA 
receptors and a homo-oligomeric GABA receptor from Drosophila melanogaster. Br. 
J. Pharmacol.14, 1363-1372.  
Risso, S., DeFelice, L.J., Blakely, R.D., 1996. Sodium-dependent GABA-induced 
currents in GATI -transfected HeLa cells. J. Physiol. 490, 691-702. 
Sánchez, M.E., Turina, A.V., García, D.A., Nolan, M.V., Perillo, M.A., 2004. Surface 
activity of thymol: implications for an eventual pharmacological activity. Colloids 
Surf. B 34, 77-85.  
Shapiro, S., Guggenheim, B., 1995. The action of thymol on oral bacteria. Oral 
Microbiol. Immunol. 10, 241-246. 
Spence, I., Drew, C., Johnston, G.A., Lodge, D., 1985. Acute effects of lead at central 
synapses in vitro. Brain Res. 333, 103–109. 
Squires, R.F., Casida, J.E., Richardson, M., Saederup, E., 1983. [35S]t-
butylbicyclophosphorothionate binds with high affinity to brain-specific sites coupled 
to γ-aminobutyric acid-A and ion recognition sites. Mol. Pharmacol. 23, 326-336. 
Squires, R.F., Saederup, E., 2000. Additivities of compounds that increase the numbers 
of high affinity [3H]muscimol binding sites by different amounts define more than 9 
GABAA receptor complexes in rat forebrain: implications for schizophrenia and 
clozapine research. Neurochem. Res. 25, 1587-1601. 
Suñol, C., Babot, Z., Fonfría, E., Galofré, M., García, D., Herrera, N., Iraola, S., 
Vendrell, I., 2008. Studies with neuronal cells: from basic studies of mechanisms of 
neurotoxicity to the prediction of chemical toxicity. Toxicol. In Vitro 22, 1350-1355. 
Suñol, C., García, D.A., Bujons, J., Krištofíková, Z., Matyas, L., Babot, Z., Kasal, A., 
2006. Activity of B-nor analogues of neurosteroids on GABAA receptor in primary 
neuronal cultures. J. Med. Chem. 49, 3225-3234. 
Supavilai, P., Karobath, M., 1984. [35S]-t-butylbicyclophosphorothionate binding sites 
are constituents of the gamma-aminobutyric acid benzodiazepine receptor complex. J. 
Neurosci. 4, 1193-1200. 
Uusi-Oukari, M., Kosonen, P., Homanics, G.E., Korpi, E.R., 2004. Brain regional 
 16
heterogeneity of pH effects on GABAA receptor-associated [35S]TBPS binding. 
Neurochem. Res. 29, 771-780. 
Vale, C., Pomés, A., Rodríguez-Farré, E., Suñol, C., 1997. Allosteric interactions 
between γ-aminobutyric acid, benzodiazepine and picrotoxinin binding sites in 
primary cultures of cerebellar granule cells. Differential effects induced by γ- and δ-
hexachlorocyclohexanes. Eur. J. Pharmacol. 319, 343-353. 
Vale, C., Vilaro, M.T., Rodriguez-Farre, E., Suñol, C., 1999. Effects of the 
conformationally restricted GABA analogues, cis- and trans-4-aminocrotonic acid, on 
GABA neurotransmission in primary neuronal cultures. J. Neurosci. Res. 57, 95-105. 
Vale, C., Fonfria, E., Bujons, J., Messeguer, A., Rodriguez-Farre, E., Suñol, C., 2003. 
The organochlorine pesticides γ-hexachlorocyclohexane (lindane), α-endosulfan and 
dieldrin differentially interact with GABAA and glycine-gated chloride channels in 
primary cultures of cerebellar granule cells. Neurosci. 37, 397–403. 
Whiting, P.J., 2003. GABAA receptor subtypes in the brain: a paradigm for CNS drug 
discovery? Drug Discov. Today 8, 445-450. 
Wooltorton, J.R., Moss, S.J., Smart, T.G., 1997. Pharmacological and physiological 
characterization of murine homomeric β3 GABAA receptors. Eur. J. Neurosci. 9, 
2225-2235. 
Zeng, C.M., Manion, B.D., Benz, A., Evers, A.S., Zorumski, C.F., Mennerick, S., 
Covey, D.F., 2005. Neurosteroid analogues. 10. The effect of methyl group 
substitution at the C-6 and C-7 positions on the GABA modulatory and anesthetic 
actions of (3α,5α)- and (3α,5β)-3-hydroxypregnan-20-one. J. Med. Chem. 48, 3051-
3059. 
 17
Figure Legends 
 
Figure 1. [35S]TBPS binding in intact cultured cortical neurons. A) [35S]TBPS (1.5-4 
nM) was incubated with TCBSS (white bars) of HBSS buffer (diagonal bars) for 30 
minutes at 25ºC, alone or in the presence of  200 µM PTX. B) Effect of GABA on 
specific [35S]TBPS binding in TCBSS buffer (squares and solid line) or HBSS buffer 
(triangles and dashed line). B: basal specific binding in the absence of added GABA. *: 
P < 0.001 with respect to basal binding. The data correspond to mean ± S.E.M. of 3 
independent experiments determined in triplicate. 
 
Figure 2. Concentration-response curves for the effects of thymol (A) and propofol (B) 
on specific [35S]TBPS binding in intact cultured cortical neurons. [35S]TBPS binding 
was performed in TCBSS (squares and solid line) or in HBSS (triangles and dashed 
line). The data correspond to 2-3 independent experiments done by triplicate for 
propofol or thymol, respectively. A minimum of 6 concentrations, all determined in 
triplicate, were used for each curve.  
 
Figure 3. Microphotographs of cultured cortical neurons incubated with TCBSS (A, C) 
or TCBSS plus 0.3% Triton X-100 (B, D). A and B are phase contrast 
microphotographs of cells after trypan blue exposure. C and D are fluorescence 
microphotographs of cells labelled with propidium iodide. Bar size: 20 µm.  
 
Figure 4. Extracellular GABA in cultured cortical neurons incubated with HBSS or 
TBSS, in the absence (white bars) or in the presence of 100 µM SKF-100330-A (black 
bars). * P < 0.01 after two way ANOVA analysis and Bonferroni post test. Results are 
mean ± S.D. of two experiments, each performed in triplicate. 
 
Figure 5. Influx of 36Cl- is potentiated in cultures incubated with Tris-NaCl buffer. 
Cultures were exposed for 30 minutes at 25ºC to TCBSS buffer (white bars) or HBSS 
buffer (diagonal bars); and then to a solution containing 0.4 μCi/ml 36Cl- in the 
corresponding buffers, in the absence or presence of 200 μM PTX. Values were 
normalized to 36Cl- uptake in the presence of PTX (considered as basal uptake) and 
correspond to mean ± S.E.M. of 3 experiments. *: P < 0.05 with respect to basal 
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binding.  
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Table 1. Parameters of thymol and propofol on the GABAA receptor. 
Compound TBPS binding Cl- influx Flunitrazepam 
binding 
 Inhibition 
(IC50, μM) 
Potentiation Potentiation 
(EC50, μM) 
Activation 
(EC50, μM) 
Potentiation 
(EC50, μM) 
In TCBSS 
25  
In TCBSS 
None  
Thymol 
 
In HBSS 
100<IC50<300  
In HBSS 
Max at ~100 μM 
 
12 a 
 
135 a 
 
131 a 
In TCBSS 
5  
In TCBSS 
None 
Propofol 
In TCBSS 
In HBSS 
In HBSS 
10<IC50<100  
In HBSS 
Max at 10 μM 
 
 
2; 3 b,d 
 
 
10; 23 c,d 
 
 
~ 20 e 
 
The values correspond to the concentrations of thymol or propofol that induce different 
effects on the GABAA receptor, taken either from this study or from cited references. In 
TBPS binding, the exposure buffer used for the parameter determination is indicated. 
Letters a to e correspond to values taken from references [8,40,6,41,42], respectively.  
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